Retina Gallery ~ Full Sized Retina Images

Library of Free, Non-Copyrighted Retina Images and Videos

Wähle Sprache:

neueste Dateien - Paraneoplastic / Auto-immune Chorioretinopathy
bdump_dastr_20211227_40.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)348 x angesehen67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/3206. Januar 2022
bdump_dastr_20211227_42.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)326 x angesehen67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/3206. Januar 2022
bdump_dastr_20211227_39.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)382 x angesehen67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/3206. Januar 2022
bdump_dastr_20211227_41.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)319 x angesehen67 year old man
Vision is better after 14 plasma exchanges, OD 20/160, OS 20/3206. Januar 2022
bdump_dastr_20211111_36.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)329 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211111_35.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)326 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211111_38_28229.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)314 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211111_37_28229.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)294 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_34.png
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)301 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_33.png
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)302 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_32.png
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)301 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_31.png
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)352 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_04.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)350 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_30.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)331 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_29.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)317 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_28.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)311 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_27.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)327 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_26.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)306 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_25.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)306 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_24.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)331 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_23.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)290 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_22.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)293 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_21.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)305 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_20.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)312 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_19.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)343 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_18.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)311 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_17.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)309 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_16.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)295 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_15.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)310 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_14.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)276 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_13.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)315 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_12.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)321 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_11.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)309 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_02.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)319 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_10.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)346 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_09.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)339 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_08.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)345 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_07.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)302 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_06.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)336 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_05.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)334 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_01.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)300 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
bdump_dastr_20211004_03.jpg
 Bilateral Diffuse Melanocytic Proliferation (BDUMP)355 x angesehen67 year old man
The patient started noticing dimming of the vision in November of 2020.  He had rapidly worsening cataracts. He had the cataract surgery done in both eyes in April of 2021.  The vision did not improve with the cataract surgery.  On June 1 of 2021 he had immunotherapy for his renal cell carcinoma and then developed severe vision loss.  The patient noticed that one of the commercials for nivolumab (checkpoint inhibitor targeting programmed death receptor-1) said it may cause vision loss.  He recalled that he started the nivolumab in October of 2020 and had vision loss starting then.    A retinal evaluation showed subretinal fluid and vision loss.   The peripheral vision and central vision were pretty good.  The vision did seem to get better off the nivolumab.  Then when the patient returned to Florida in September and now the vision is getting worse.  The patient did not have any treatments in either eye.  The patient is now off the oncology treatment.  He was then started on a TKI cabometex for the cancer which was dosed in mid June through mid July just for a month.  It was stopped because of a skin rash and reactions.  
VA OD: Dcc20/200-2 PHNI Ncc20/800
VA OS: Dcc20/63 PHNI NccJ7 He has been off the checkpoint inhibitor for a year.06. Januar 2022
mvmd_kava_062218_25.jpg
 Multifocal Vitelliform Macular Dystrophy530 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_24.jpg
 Multifocal Vitelliform Macular Dystrophy497 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_22.jpg
 Multifocal Vitelliform Macular Dystrophy477 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_23.jpg
 Multifocal Vitelliform Macular Dystrophy475 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_21.jpg
 Multifocal Vitelliform Macular Dystrophy464 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_20.jpg
 Multifocal Vitelliform Macular Dystrophy462 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_19.jpg
 Multifocal Vitelliform Macular Dystrophy444 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_18.jpg
 Multifocal Vitelliform Macular Dystrophy410 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_17.jpg
 Multifocal Vitelliform Macular Dystrophy474 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_16.jpg
 Multifocal Vitelliform Macular Dystrophy474 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_15.jpg
 Multifocal Vitelliform Macular Dystrophy434 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_14.jpg
 Multifocal Vitelliform Macular Dystrophy504 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_13.jpg
 Multifocal Vitelliform Macular Dystrophy452 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_12.jpg
 Multifocal Vitelliform Macular Dystrophy503 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_10.jpg
 Multifocal Vitelliform Macular Dystrophy454 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_11.jpg
 Multifocal Vitelliform Macular Dystrophy466 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_09.jpg
 Multifocal Vitelliform Macular Dystrophy474 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_08.jpg
 Multifocal Vitelliform Macular Dystrophy416 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_07.jpg
 Multifocal Vitelliform Macular Dystrophy415 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_04.png
 Multifocal Vitelliform Macular Dystrophy445 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_06.jpg
 Multifocal Vitelliform Macular Dystrophy429 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_05.jpg
 Multifocal Vitelliform Macular Dystrophy522 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_03.png
 Multifocal Vitelliform Macular Dystrophy580 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_02.png
 Multifocal Vitelliform Macular Dystrophy469 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
mvmd_kava_062218_01.png
 Multifocal Vitelliform Macular Dystrophy633 x angesehen58 year old female with mild vision loss - 20/20 OU - extensive testing has shown no cancer. Case of Karina Findlay, MD06. Mai 2019
auret_chja_022419_46.jpg
 Autoimmune Retinopathy452 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_45.jpg
 Autoimmune Retinopathy451 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_44.jpg
 Autoimmune Retinopathy487 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_43.jpg
 Autoimmune Retinopathy450 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_41.jpg
 Autoimmune Retinopathy496 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_42.jpg
 Autoimmune Retinopathy530 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_40.jpg
 Autoimmune Retinopathy478 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_39.jpg
 Autoimmune Retinopathy458 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_38.jpg
 Autoimmune Retinopathy455 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_37.jpg
 Autoimmune Retinopathy464 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_36.jpg
 Autoimmune Retinopathy466 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_35.jpg
 Autoimmune Retinopathy489 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_34.jpg
 Autoimmune Retinopathy553 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_33.jpg
 Autoimmune Retinopathy501 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_32.jpg
 Autoimmune Retinopathy522 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_31.jpg
 Autoimmune Retinopathy456 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_30.jpg
 Autoimmune Retinopathy520 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_29.jpg
 Autoimmune Retinopathy427 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_27.jpg
 Autoimmune Retinopathy452 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_28.jpg
 Autoimmune Retinopathy480 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_26.jpg
 Autoimmune Retinopathy485 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_24.jpg
 Autoimmune Retinopathy501 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_25.jpg
 Autoimmune Retinopathy483 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_23.jpg
 Autoimmune Retinopathy522 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_22.jpg
 Autoimmune Retinopathy441 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_21.jpg
 Autoimmune Retinopathy486 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_20.jpg
 Autoimmune Retinopathy536 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_19.jpg
 Autoimmune Retinopathy652 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_17.jpg
 Autoimmune Retinopathy585 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_18.jpg
 Autoimmune Retinopathy467 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_16.jpg
 Autoimmune Retinopathy459 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_15.jpg
 Autoimmune Retinopathy444 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
auret_chja_022419_14.jpg
 Autoimmune Retinopathy496 x angesehen91 year old female with severe vision loss over the past 3 years. She has shimmery scotomas. The main findings are outer retinal atrophy evident on OCT and FAF. VA 20/80 OD and 20/125 OS06. Mai 2019
135 Dateien auf 2 Seite(n) 12